7 preferential subscription rights will entitle their holder to
subscribe to 1 new ordinary share
STRASBOURG, France--(BUSINESS WIRE)--
Not for distribution in or into Canada, Japan or Australia.
communication is not offering material and is for information purposes
Transgene (Paris:TNG) (Euronext Paris: FR0005175080), a French
biopharmaceutical company focused on discovering, developing and
manufacturing targeted immunotherapies for the treatment of cancer and
infectious diseases, announces today the launch of a rights issue aiming
to raise 45.5 million euros.
The terms and conditions of the rights issue are described in a
prospectus (containing Transgene’s Document de RÉfÉrence 2012,
its update and a note d’opÉration) that has received the visa
N°14-062 dated February 27, 2014 from the French AutoritÉ des marchÉs
This refinancing will enable Transgene to strengthen its financial
situation in order to advance its clinical development programs, in
particular the preparation of the Phase 3 studies for TG4010 (non-small
cell lung cancer) and Pexa-Vec (advanced liver cancer).
Institut MÉrieux, which currently owns 54.87% of Transgene’s share
capital through its subsidiary TSGH, has communicated to Transgene its
commitment to fully subscribe to its pro rata share of the rights
offering and that it may subscribe for an additional amount on a
reducible basis (souscription À titre rÉductible).
Institut MÉrieux stated: “We fully support Transgene’s decision to
reinforce its financial position before entering into late-stage
clinical development of its two programs, TG4010 and Pexa-Vec. At the
present valuation and the proposed terms, this capital increase gives us
the opportunity to consolidate our position in Transgene at the
threshold of a new development stage of the Company”.
A portion of the remainder of the rights issue will be guaranteed by a
bank so that, together with Institut MÉrieux’s commitment, at least 75%
of the rights issue will be underwritten1 (taking into
account the number of shares necessary for the exercise of the
preferential subscription right of the beneficiaries of stock options
who would have exercised their options).
A number of U.S. institutional investors that are not yet shareholders
of Transgene have expressed their interest to acquire a direct
shareholding in Transgene’s capital. In the case these investors should
confirm their willingness to invest in Transgene’s shares and cannot do
so in the rights offering, the Company may decide to proceed with a
private placement of up to a maximum of 2 million shares directed at
these qualified investors only after the rights offering.
As of December 31, 2013, the Company’s cash and cash equivalents,
available-for-sale financial assets and other current financial assets
amounted to 47.9 million euros. Given the Company’s anticipated net cash
burn of approximately 50 to 55 million euros for the next twelve months,
the rights issue launched today will enable the Company to have
sufficient working capital to meet its requirements for the next twelve
months, even if Novartis does not exercise its option on TG4010.
Transgene believes that the proceeds of the refinancing should allow it
to extend its cash horizon to 2016 if Novartis exercises its option on
TG4010. Should Novartis not exercise its option on this program, the
Company will seek another strategic partner. However, its cash horizon
would be 2015 in the absence of a partner for this product. These cash
horizons will remain unchanged even if only 75% of the capital increase
Terms and conditions of the rights issue
Transgene is offering 4 553 551 new ordinary shares2
at a subscription price of 10 euros per share. All existing Transgene
shareholders, both in France and outside France, will be entitled to
receive one preferential subscription right for every share held as of
the close of trading on February 28, 2014. Holders of preferential
subscription rights will be able to subscribe and/or sell all, or part,
of their rights. Seven preferential subscription rights will entitle
their holder to subscribe for 1 new ordinary share by irrevocable
entitlement (souscription À titre irrÉductible), at a
subscription price of 10 euros per new ordinary share. Shareholders will
also be entitled to subscribe for new ordinary shares on a reducible
basis (souscription À titre rÉductible).
On the basis of Transgene’s closing share price on February 26, 2014,
i.e. 13.43 euros, the subscription price of €10 euros represents a
23.08% discount to the theoretical ex-right price, with the theoretical
value of a preferential subscription right amounting to 0.43 euros.
The subscription period will be open from March 3, 2014, to March 14,
2014 inclusive. During this period, the preferential subscription rights
will be listed and traded on Euronext Paris (ISIN:FR0005175080).
The offering will be open to the public only in France. The settlement,
delivery and listing of the new ordinary shares is expected to take
place on March 27, 2014. The newly issued Transgene shares will have a
nominal value of 2.28810183 euros and an issue premium of 7.711189817
euros, and will be fungible with existing shares listed on Euronext
Paris (ISIN: FR0005175080).
Transgene (NYSE-Euronext: TNG), a member of the Institut MÉrieux Group,
is a publicly traded French biopharmaceutical company focused on
discovering, developing and manufacturing targeted immunotherapies for
the treatment of cancer and infectious diseases. Transgene’s programs
utilize well-tolerated viruses with the goal of indirectly or directly
killing infected or cancerous cells. The Company’s four clinical-stage
programs are: TG4010 for non-small cell lung cancer; Pexa-Vec for liver
cancer; TG4001 for oropharyngeal cancer (under a collaboration agreement
with the EORTC) and TG4040 for chronic Hepatitis C. Transgene has
concluded corporate strategic agreements for the development of two of
its immunotherapy products: an exclusive option agreement with Novartis
for the development and commercialization of TG4010 and an in-licensing
agreement with U.S.-based Jennerex, Inc. for the development and
commercialization of Pexa-Vec in certain territories. The Company also
has several programs in research and pre-clinical development that are
based on its core viral vector technology.
Transgene is based in Strasbourg, France, and has additional operations
in Lyon, as well as satellite offices in China and the U.S.
A prospectus approved by the AMF under visa No 14-062 on February 27,
2014 comprised of the Document de RÉfÉrence filed with the AMF
under number D.13-0315 on April 9, 2013 and its update filed with the
AMF under number D.13-0315-A01 on February 27, 2014 and the note
d’opÉration (including a summary of the prospectus), may be obtained
free of charge from Transgene, as well as on the websites of Transgene (www.transgene.fr)
and the AMF (www.amf-france.org).
For a discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from forward-looking statements, please refer to
the Risk Factors section of the Company’s Document de RÉfÉrence
and its update filed with the AMF, which are available on the AMF
or on Transgene’s website (http://www.transgene.fr).
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Transgene in any country.
With respect to the member states of the European Economic Area which
have implemented the Directive 2003/71/EC of the European Parliament and
the Council ofNovember 4, 2003 (as amended, the “Prospectus Directive”),
no action has been undertaken or will be undertaken to make an offer to
the public of the securities referred to herein requiring the
publication of a prospectus in any relevant member state. As a result,
the securities may not and will not be offered in any relevant member
state except in accordance with the exemptions set forth in Article 3(2)
of the Prospectus Directive, if they have been implemented in that
relevant member state, or under any other circumstances which do not
require the publication by Transgene of a prospectus pursuant to Article
3 of the Prospectus Directive and/or to applicable regulations of that
relevant member state.
This press release is not an offer of securities for sale in the
United States or any other jurisdiction. Securities may not be sold or
offered in the United States unless they are registered or are exempt
from the registration requirements of the U.S. Securities Act of 1933,
as amended. Transgene does not intend to register any portion of this
offering in the United States or to conduct a public offering of
securities in the United States.
In the United Kingdom, this press release is only being distributed to,
and is only directed at, persons that (i) are “investment professionals”
(falling within Article 19(5) of the Financial Services and Markets Act
2000 (Financial Promotion) Order 2005 (as amended, the "Order"),
(ii) are persons falling within Article 49(2)(a) to (d) ("high net worth
companies, unincorporated associations, etc.") of the Order, or (iii)
are persons to whom an invitation or inducement to engage in investment
activity (within the meaning of section 21 of the Financial Services and
Markets Act 2000) in connection with the issue or sale of any securities
may otherwise lawfully be communicated or caused to be communicated (all
such persons together being referred to as "relevant persons").
In the United Kingdom, this press release is directed only at relevant
persons and must not be acted on or relied on by persons who are not
relevant persons. Any investment or investment activity to which this
press release relates is available only to relevant persons and will be
engaged in only with relevant persons.
It may be unlawful to distribute this press release in certain
jurisdictions. This press release is not for distribution in Canada,
Japan or Australia.
1 Under French law, the rights issue will not take place, and
all subscriptions will be cancelled, if at least 75% of its amount is
not subscribed for by shareholders or third parties.
2 The number of new shares may be increased to 4 679 585 if
all of the outstanding and exercisable stock options are exercised
before March 9, 2014 at 11.59pm CET, resulting in the size of the rights
issue to be therefore increased to a maximum of 46 795 850 euros.
Elisabetta Castelli, Director, Investor Relations,
(0)3 88 27 91 21
Laurie Doyle, Director, Investor Relations U.S. &
+1 (339) 832 0752
+49 89 210 228 30
+44 207 148 5998